Picture of Ergomed logo

ERGO Ergomed News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

REG - Ergomed plc - Notice of Preliminary Results




 



RNS Number : 9220E
Ergomed plc
04 March 2020
 

 PRESS RELEASE

 

 

Notice of Preliminary Results

 

 

Guildford, UK - 4 March 2020: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its preliminary results for the year ending 31 December 2019 on 25 March 2020.

 

Miroslav Reljanović, Executive Chairman, Richard Barfield, Chief Financial Officer and Lewis Cameron, Chief Operating Officer will host a presentation and conference call for analysts at 9.30am GMT on the day of the results at the offices of Numis, 10 Paternoster Square, London EC4M 7LT.

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Sue Stuart

ergomed@consilium-comms.com

Matthew Neal / Olivia Manser




 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORJIMMTMTBMMBM

Recent news on Ergomed

See all news